CTIS2023-505967-36-00招募中1 期
A Translational Phase 1B, 2-Part Study to Evaluate Pharmacokinetics, Safety and Pharmacodynamics of Treatment with ATX-304 Na Salt Tablets.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Betagenon AB
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
Mechanistic study of the effect of itepekimab on airway inflammation in patients with COPDMedDRA version: 26.1Level: PTClassification code: 10009033Term: Chronic obstructive pulmonary disease Class: 100000004855Chronic Obstructive Pulmonary DiseaseCTIS2024-512007-39-00Sanofi-Aventis Recherche & Developpement102
进行中（未招募）
1 期
Mechanistic study of the effect of itepekimab on airway inflammation in patients with COPDMedDRA version: 26.1Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersChronic Obstructive Pulmonary DiseaseEUCTR2021-001654-65-DESanofi-Aventis Recherche & Developpement109
进行中（未招募）
1 期
Mechanistic study of the effect of itepekimab on airway inflammation in patients with COPDMedDRA version: 21.1Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersChronic Obstructive Pulmonary DiseaseEUCTR2021-001654-65-NLSanofi-Aventis Recherche & Developpement109
进行中（未招募）
1 期
Mechanistic study of the effect of itepekimab on airway inflammation in patients with COPDChronic Obstructive Pulmonary DiseaseEUCTR2021-001654-65-DKSanofi-Aventis Recherche & Developpement109
招募中
2 期
A Phase 2a, open label, two-part study to evaluate the mechanism of action of itepekimab (anti-IL-33 mAb) on airway inflammation in patients with chronic obstructive lung disease (COPD)Chronic Obstructive Pulmonary DiseaseChronic bronchitisNL-OMON52084Sanofi BV3